Here’s what you should know:
1. Kansas City, Mo.-based Kansas School of Medicine’s Prashanth Vennalaganti, MD, and colleagues led a multicenter, prospective, randomized tandem center study through 16 U.S. gastroenterology centers.
2. Of 160 high-risk patients, Wats3D detected 29 HGD/EAC cases. The Seattle random forceps biopsy only detected seven.
3. Researchers concluded the Seattle random forceps biopsy was severely limited, and although Wats3D takes a “few extra minutes” the results were valuable.
4 Incoming Chief of Gastroenterology at New York City-based Mount Sinai West Michael Smith, MD, said in a release, “I can think of very few high impact studies in the field of Barrett’s esophagus that should change how gastroenterologists, both community-based and academic, care for their patients, and this study is one of them. These robust data demonstrate we have a tool that markedly improves our ability to detect dysplasia and cancer within Barrett’s well beyond the error-prone Seattle protocol.”
More articles on gastroenterology:
GI center to know: Center for Colonoscopy Excellence
Metro Health adds seven gastroenterologists — 3 key notes
GI leader to know: Dr. Frank Farrell of Center for Colonoscopy Excellence
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
